Fang Xie - Upstream Bio, Vice Biometrics
| UPB Stock | 21.26 2.30 12.13% |
Executive
Fang Xie is Vice Biometrics of Upstream Bio,
| Address | 890 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 781 208 2466 |
| Web | https://upstreambio.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Gray | Vigil Neuroscience | 49 | |
| Christopher Hayes | Verrica Pharmaceuticals | 60 | |
| Beatrix StelteLudwig | Vincerx Pharma | N/A | |
| Mr DABT | Vigil Neuroscience | 51 | |
| Michael Faerm | Viracta Therapeutics | 57 | |
| Nate Sanburn | Verastem | N/A | |
| Park CPA | Vigil Neuroscience | N/A | |
| Michael Crowther | Verastem | N/A | |
| Christopher JD | Vigil Neuroscience | 49 | |
| Peter Spargo | Verona Pharma PLC | 62 | |
| Christopher Martin | Verona Pharma PLC | N/A | |
| Colleen Mockbee | Verastem | N/A | |
| Joe Bonaccorso | Verrica Pharmaceuticals | 60 | |
| John MD | Verastem | 47 | |
| Kelly Neelon | Vigil Neuroscience | N/A | |
| Dr MBA | Verrica Pharmaceuticals | 48 | |
| Kathleen MD | Verona Pharma PLC | 66 | |
| Robert McRae | Viracta Therapeutics | N/A | |
| Biljana PharmD | Viracta Therapeutics | N/A | |
| Cheryl Madsen | Viracta Therapeutics | N/A | |
| Karen MBA | Vincerx Pharma | N/A | |
Upstream Bio, Leadership Team
Elected by the shareholders, the Upstream Bio,'s board of directors comprises two types of representatives: Upstream Bio, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Upstream. The board's role is to monitor Upstream Bio,'s management team and ensure that shareholders' interests are well served. Upstream Bio,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Upstream Bio,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Parika MS, Head Operations | ||
| Maryse MS, VP Operations | ||
| Aaron MD, Chief Development | ||
| Sumathi MD, VP Development | ||
| Fang Xie, Vice Biometrics | ||
| Mersedeh PharmD, Senior Quality | ||
| Adam MBA, Chief Officer | ||
| Lisa Fiering, Senior Culture | ||
| William Collins, Secretary | ||
| MD MPH, CEO Director |
Upstream Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Upstream Bio, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Upstream Bio, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio, Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Upstream Bio,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio,. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Upstream Bio, is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio,'s market value can be influenced by many factors that don't directly affect Upstream Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.